简体中文
繁體中文
English
Pусский
日本語
ภาษาไทย
Tiếng Việt
Bahasa Indonesia
Español
हिन्दी
Filippiiniläinen
Français
Deutsch
Português
Türkçe
한국어
العربية
Abstract:HYDERABAD, Nov 7 (Reuters) - Indian generic drugmaker Zydus Lifesciences Ltd (ZYDU.NS) reported a better-than-expected 53.3% jump in quarterly profit on Tuesday, led by the strong sales in the domestic market and the United States.
HYDERABAD, Nov 7 (Reuters) - Indian generic drugmaker Zydus Lifesciences Ltd (ZYDU.NS) reported a better-than-expected 53.3% jump in quarterly profit on Tuesday, led by the strong sales in the domestic market and the United States.
Consolidated net profit was 8.01 billion rupees ($96.2 million) in the quarter ended Sept 30, compared with 5.23 billion rupees a year earlier. Analysts, on an average, expected a profit of 7.58 billion rupees, per LSEG data.
Total revenue from operations rose 9.1% to 43.69 billion rupees, boosted by the strength in U.S. formulation segment, which constitutes 44% of the business.
Indias generic drug makers, which draw a significant share of revenue from the crucial U.S. market, are recovering from the effects of eroding prices in the largest drug market in the world.
Zydus U.S. formulation revenue rose 9.2%. The company had in August said the business will be boosted by the sales of lenalidomide capsules, a copy of popular cancer drug Revlimid, through the year.
The company, which also makes complex biological drugs biosimilars and vaccines, reported a 4.8% rise in India revenue.
“Going ahead, differentiated launches in the U.S., in addition to a rebound in India business growth which was constrained by delayed seasonality, will be critical drivers,” Managing Director Sharvil Patel said in a statement.
Patel expects sustained growth in profit this fiscal year, with a more than 24% margin on earnings before interest taxes, depreciation and amortisation.
Shares of Zydus rose 1.34% after the results, compared to a 1.12% rise in the Nifty Pharma index.
On Monday, unit Zydus Wellness Ltd (ZYDS.NS), which makes consumer brands, reported a more than 30% drop in second-quarter profit, hit by a one-off tax expense. read more
Last month, rivals Dr Reddys (REDY.NS) and Cipla (CIPL.NS), topped quarterly profit estimates, led by strong U.S. demand.
($1 = 83.2580 Indian rupees)
Disclaimer:
The views in this article only represent the author's personal views, and do not constitute investment advice on this platform. This platform does not guarantee the accuracy, completeness and timeliness of the information in the article, and will not be liable for any loss caused by the use of or reliance on the information in the article.